



NDA 50420/S-080
NDA 50627/S-023

SUPPLEMENT APPROVAL

sanofi-aventis U.S. LLC
Attention: Ying Zheng
Senior Associate, Regulatory Affairs
55 Corporate Drive
Mail Stop: 55C-205A
Bridgewater, NJ 08807

Dear Ms. Zheng:

Please refer to your Supplemental New Drug Applications (sNDAs) dated August 31, 2018, received August 31, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for RIFADIN (rifampin capsules USP), 150 mg and 300 mg [NDA 50420] and RIFADIN IV (rifampin for injection USP) [NDA 50627].

These “Changes Being Effected” supplemental new drug applications provide for the following changes to the package insert (PI): Revision of the **WARNINGS** section, and the **ADVERSE REACTIONS** section, **Hematologic** subsection, to add information regarding vitamin-K dependent coagulation disorders and bleeding. Minor editorial revisions were also made throughout the PI.

APPROVAL & LABELING

We have completed our review of these supplemental application, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Mr. Gregory DiBernardo, Regulatory Project Manager, at (301) 796-4063.

Sincerely,

{See appended electronic signature page}

Joseph G. Toerner, M.D., M.P.H.
Deputy Director for Safety
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE:
Package Insert

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JOSEPH G TOERNER
02/28/2019 01:54:38 PM